Back to Authors

Kumar, Prashant

0000-0001-8975-5108

Mayo Clinic

Institute of Bioinformatics, International Tech Park, Bangalore 560066, India.

Citations 4

Integrated Proteomic and Phosphoproteomics Analysis of DKK3 Signaling Reveals Activated Kinase in the Most Aggressive Gallbladder Cancer
Gondkar, Kirti , Joshi, Neha , Pandey, Akhilesh , Kumar, Prashant , Kumar, Prashant , Pandey, Akhilesh , Joshi, Neha S , Sathe, Gajanan , Nair, Bipin G.

Cells | February 28, 2021 | Volume: 10 | Issue: 3 | Pages: 511

10.3390/cells10030511 Get It

DKK3 is a secreted protein, which belongs to a family of Wnt antagonists and acts as a potential tumor suppressor in gallbladder cancer. To further understand its tumor suppressor functions, we overexpressed DKK3 in 3 GBC cell lines. We have employed high-resolution mass spectrometry and tandem mass tag (TMT) multiplexing technology along with immobilized metal affinity chromatography to enrich phosphopeptides to check the downstream regulators. In this study, we reported for the first time the alteration in the phosphorylation of 14 kinases upon DKK3 overexpression. In addition, we observed DKK3 induced hyper phosphorylation of 2 phosphatases: PPP1R12A and PTPRA, which have not been reported previously. Canonical pathway analysis of altered molecules indicated differential enrichment of signaling cascades upon DKK3 overexpression in all the 3 cell lines. Protein kinase A signaling, Sirtuin signaling pathway, and Cell Cycle Control of Chromosomal Replication were observed to be differentially activated in the GBC cell lines. Our study revealed, DKK3 overexpression has differential effect based on the aggressive behavior of the cell lines. This study expands the understanding of DKK3-mediated signaling events and can be used as a primary factor for understanding the complex nature of this molecule.
Is the Proteome of Bronchoalveolar Lavage Extracellular Vesicles a Marker of Advanced Lung Cancer?
Carvalho, Ana Sofía , Moraes, Maria Carolina Strano , Na, Chan Hyun , Fierro-Monti, Ivo , Henriques, Andreia , Zahedi, Sara , Tranfield, Erin M. , Sousa, Ana Laura , Farinho, Ana , Rodrigues, Luís Vaz , Pinto, Paula , Bárbara, Cristina , Mota, Leonor, Abreu, Tiago , Semedo, Júlio, Seixas, Susana , Kumar, Prashant , Costa‐Silva, Bruno , Pandey, Akhilesh , Matthiesen, Rune , Sousa, Ana Laura , Rodrigues, Luís Vaz , Pinto, Paula , Bárbara, Cristina , Seixas, Susana , Kumar, Prashant , Costa-Silva, Bruno , Pandey, Akhilesh , Matthiesen, Rune , Bodo, Cristian

Cancers | November 20, 2020 | Volume: 12 | Issue: 11 | Pages: 3450

10.3390/cancers12113450 Get It

Acellular bronchoalveolar lavage (BAL) proteomics can partially separate lung cancer from non-lung cancer patients based on principal component analysis and multivariate analysis. Furthermore, the variance in the proteomics data sets is correlated mainly with lung cancer status and, to a lesser extent, smoking status and gender. Despite these advances BAL small and large extracellular vehicles (EVs) proteomes reveal aberrant protein expression in paracrine signaling mechanisms in cancer initiation and progression. We consequently present a case-control study of 24 bronchoalveolar lavage extracellular vesicle samples which were analyzed by state-of-the-art liquid chromatography-mass spectrometry (LC-MS). We obtained evidence that BAL EVs proteome complexity correlated with lung cancer stage 4 and mortality within two years´ follow-up (p value = 0.006). The potential therapeutic target DNMT3B complex is significantly up-regulated in tumor tissue and BAL EVs. The computational analysis of the immune and fibroblast cell markers in EVs suggests that patients who deceased within the follow-up period display higher marker expression indicative of innate immune and fibroblast cells (four out of five cases). This study provides insights into the proteome content of BAL EVs and their correlation to clinical outcomes.
Urinary glycoproteomic profiling of non-muscle invasive and muscle invasive bladder carcinoma patients reveals distinct N-glycosylation pattern of CD44, MGAM, and GINM1
George, Irene A., Deb, Barnali, Jain, Ankit , Nayak, Brusabhanu , Seth, Amlesh , Pandey, Akhilesh , Kumar, Prashant , Pandey, Akhilesh , Kumar, Prashant , Sathe, Gajanan , Patel, Krishna , Karmakar, Subhradip

Oncotarget | August 25, 2020 | Volume: 11 | Issue: 34 | Pages: 3244-3255

10.18632/oncotarget.27696 Get It

Quantitative Proteomics of Urinary Bladder Cancer Cell Lines Identify UAP1 as a Potential Therapeutic Target
Puttamallesh, Vinuth N., Deb, Barnali, Gondkar, Kirti , Jain, Ankit , Nair, Bipin G. , Pandey, Akhilesh , Chatterjee, Aditi , Kumar, Prashant , Kumar, Prashant , Pandey, Akhilesh , Gowda, Harsha

Genes | July 10, 2020 | Volume: 11 | Issue: 7 | Pages: 763

10.3390/genes11070763 Get It

Bladder carcinoma (BC) incidence and mortality rates are increasing worldwide. The development of novel therapeutic strategies is required to improve clinical management of this cancer. Aberrant protein expression may lead to cancer initiation and progression. Therefore, the identification of these potential protein targets and limiting their expression levels would provide alternative treatment options. In this study, we utilized a liquid-chromatography tandem mass spectrometry-based global proteomics approach to identify differentially expressed proteins in bladder cancer cell lines. A total of 3913 proteins were identified in this study, of which 479 proteins were overexpressed and 141 proteins were downregulated in 4 out of 6 BC cell lines when compared with normal human urothelial cell line (TERT-NHUC). We evaluated the role of UDP-N-acetylhexosamine pyrophosphorylase (UAP1) in bladder cancer pathogenesis. The silencing of UAP1 led to reduction in proliferation, invasion, colony formation and migration capability of bladder cancer cell lines. Thus, our study reveals UAP1 as a promising therapeutic target for bladder cancer.